News
The Association of American Physicians and Surgeons (AAPS) filed its amicus brief in the U.S. Supreme Court on June 12 against a Colorado ban on conversion therapy for minors, in Chiles v. Salazar (No ...
MONTREAL, June 16, 2025 (GLOBE NEWSWIRE) -- The Biocodex Microbiota Foundation, an organization founded by Biocodex and dedicated to inspiring scientific projects that explore the microbiome, is ...
MediPharm wishes to assure its shareholders that as the Meeting has not yet taken place, the results are not yet available. MediPharm will announce the final results of the Meeting in the ordinary ...
NEW HAVEN, Conn., June 16, 2025 (GLOBE NEWSWIRE) -- Management of specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) is requesting that shareholders instruct their brokers to vote ...
MENLO PARK, Calif., June 16, 2025 (GLOBE NEWSWIRE) -- Inquis Medical, the leading innovator in the treatment of venous thromboembolic disease, today announced that its AVENTUS Thrombectomy System has ...
AI meets genomics in BioAro’s latest launch, unlocking faster, scalable drug discovery. PanOmiQ™ Research sets a new global benchmark for precision health innovation.
The BIO International Convention provides an ideal platform to showcase how FibroBiologics is potentially transforming the treatment landscape for chronic diseases,” said Pete O’Heeron. “With our ...
Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) today announced submission of its response to the U.S. Food and Drug Administration (FDA)’s Complete Response Letter (CRL) regarding its New Drug ...
As previously reported, on February 28, 2025, Alzamend entered into a Securities Purchase & Exchange Agreement (the “ Agreement ”) with a sophisticated investor (the “ Investor ”), pursuant to which ...
Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) announced that it has declared a cash dividend of C$0.042 per common share of the Company for the month of June 2025, which is payable on ...
RESEARCH TRIANGLE PARK, N.C., June 16, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new data on the long-term efficacy and safety of ORLADEYO ® (berotralstat) ...
GLP-1/GIP receptor co-agonist designed to be highly potent and for once-monthly administration based on MBX’s novel PEP™ platform technology . Phase 1 trial of MBX 4291 is exp ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results